检索结果-南通市图书馆

Chemical Research in Chinese Universities 2011年第1期27卷 15-18页

作者： dong zhong-ping hu bin chen yan yuan hong-ming feng shou-hua State Key Laboratory of Inorganic Synthesis ＆ Preparative Chemistry College of Chemistry Jilin University Changchun 130012 P. R. China

Polycrystallines Bi0.5Ca0.5-xLaxFe0.3Mn0.7O3（x=0, 0,05, 0.10, 0.15, 0.20, 0.25） were prepared by molten salt method and showed perovskite orthorhombic structure with space group Pnma. The magnetic measurements indicate that the compounds exhibit antiferromagnetic behavior in a temperature range of 4-300 K. The measurements of transport properties suggest that the substitution of La for Ca enhanced the conductivity, and a kink appeared on the curve of temperature dependence of resistivity at 275 K, which is related to the spin-reorientation in the samples.

关键词： Perovskite Doping Magnetism Spin-reorientation

Hydrothermal Synthesis and Characterization of Pyrochlore Titanate R_2Ti_2O_7(R=Gd^(3+),Tb^(3+),Dy^(3+))

在线全文

学校读者我要写书评

暂无评论

Chemical Research in Chinese Universities 2011年第2期27卷 161-165页

作者： PENG Wen hu bin chen yan hu Wei-wei GUO Li yuan hong-ming feng shou-hua State Key Laboratory of Inorganic Synthesis and Preparative Chemistry College of Chemistry Jilin University Changchun 130012 P. R. China

Pyrochlore titanate oxides, R2Ti2O7（R=Gd3＋, Tb3＋, Dy3＋）, were synthesized under mild hydrothermal conditions. The crystal growth of pyrochlore titanate oxides and taking place of chemical reaction in the hydrothermal processing were sensitive to the alkalinity, temperature, reaction time, the nature of the rare earth ion and the composition of initial reaction mixture. The as-prepared samples were characterized by powder X-ray diffraction, scanning electron microscopy, Raman spectrum and variable temperature dc magnetic susceptibility（Superconductivity quantum interference device, SQUIDS）. The magnetic studies gave 7.29×10-23 A·m2/Gd3＋ and -8.28 K, 8.75×10-23 A·m2/ Tb3＋ and -19.7 K, and 8.85×10-23 A·m2/Dy3＋ and 0.84 K effective moments and Weiss constants for Gd2Ti2O7, Tb2Ti2O7 and Dy2Ti2O7, respectively.

关键词： Pyrochlore Titanate Hydrothermal

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

在线全文

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2020年第12期33卷 893-905页

作者： MA yan Zhu dong Shan chen Ren Bo SHI Nan Nan LIU Si hong FAN Yi Pin WU Gui hui yanG Pu Ye BAI Jiang feng chen hong chen Li Ying feng Qiao GUO Tuan Mao HOU Yong hu Gui Fen hu Xiao Mei hu Yun hong huaNG Jin huaNG Qiu hua huaNG Shao Zhen JI Liang JIN Hai Hao LEI Xiao LI Chun yan LI Min Qing LI Qun Tang LI Xian Yong LIU hong De LIU Jin ping LIU Zhang MA Yu Ting MAO Ya MO Liu Fen NA hui WANG Jing Wei SONG Fang Li SUN Sheng WANG dong Ting WANG ming Xuan WANG Xiao yan WANG Yin Zhen WANG Yu dong WU Wei WU Lan ping XIAO yan hua XIE Hai Jun XU hong ming XU shou Fang XUE Rui Xia yanG Chun yanG Kai Jun yuan Sheng Li ZHANG Gong Qi ZHANG Jin Bo ZHANG Lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun Zhu Jun Teng Zhu Tian Qing ZHANG hua Min WANG yan ping WANG Yong yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health Management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome

Lung-protective Ventilation in Patients with Brain Injury： A Multicenter Cross-sectional Study and Questionnaire Survey in China

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2016年第14期129卷 1643-1651页

作者： Xu-Ying Luo Ying-hong hu Xiang-yuan Cao yan Kang Li-ping Liu shou-hong Wang Rong-Guo Yu Xiang-You Yu Xia Zhang Bao-Shan Li Zeng-Xiang Ma Yi-bing Weng Heng Zhang De-Chang chen Wei chen Wen-Jin chen Xiu-Mei chen bin Du Mei-Li Duan Jin hu Yun-feng Hoang Gui-Jun Jia Li-hong Li Yu-Min Liang bing-Yu Qin Xian-dong Wang Jian Xiong Li-Mei yan Zheng-ping yang chen-ming dong dong-Xin Wang Qing-yuan Zhan Shuang-Lin FU Lin Zhao Qi-bing huang Ying-Guang Xie Xiao-Bo huang Guo-bin Zhang Wang-bin Xu yuan Xu YaLing Liu He-Ling Zhao Rong-Qing Sun ming Sun Qing-hong cheng Xin Qu Xiao-feng yang ming Xu zhong-hua Shi Han chen Xuan He yan-Lin yang Guang-Qiang chen Xiu-Mei Sun Jian-Xin Zhou Department of Critical Care Medicine Beijing Tiantan Hospital Capital Medical University Beijing 100050 China Department of Critical Care Medicine Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang 310009 China Department of Critical Care Medicine General Hospital of Ningxia Medical University Yinchuan Ningxia 750004 China Department of Critical Care Medicine West China Hospital Sichuan University Chengdu Sichuan 610041 China Neurological Intensive Care Unit Beijing Tiantan Hospital Capital Medical University Beijing 100050 China Department of Critical Care Medicine Guangdong General Hospital Guangzhou Guangdong 510000 China Surgical Intensive Care Unit Fujian Province Hospital Fuzhou Fujian 350000 China Department of Critical Care Medicine First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China Department of Critical Care Medicine Bethune International Peace Hospital Shijiazhuang Hebei 050000 China Department of Critical Care Medicine Yuncheng Central Hospital Yuncheng Shanxi 044000 China Department of Emergency and Critical Care Medicine Cangzhou People's Hospital Cangzhou Hebei 061000 China Department of Critical Care Medicine Beijing Luhe Hospital Capital Medical University Beijing 101100 China Department of Critical Care Medicine First Hospital of China Medical University Shenyang Liaoning 110000 China Department of Critical Care Medicine Shanghai Changzheng Hospital Shanghai 200000 China Department of Critical Care Medicine Beijing Shijitan Hospital Capital Medical University Beijing 100038 China Department of Critical Care Medicine Xuanwu Hospital Capital Medical University Beijing 100053 China Department of Critical Care Medicine Miyun County Hospital Beijing 100038 China Medical Intensive Care Unit Peking Union Medical College Hospital Beijing 101500 China Department of Critical Care Medicine Beijing Friendship Hospital Capital Medical University Beijing 100050 Chin

Background： Over the years, the mechanical ventilation （MV） strategy has changed worldwide. The aim of the present study was to describe the ventilation practices, particularly lung-protective ventilation （LPV）, among brain-injured patients in China. Methods： This study was a multicenter, 1-day, cross-sectional study in 47 Intensive Care Units （ICUs） across China. Mechanically ventilated patients （18 years and older） with brain injury in a participating ICU during the time of the study, including traumatic brain injury, stroke, postoperation with intracranial tumor, hypoxic-ischemic encephalopathy, intracranial infection, and idiopathic epilepsy, were enrolled. Demographic data, primary diagnoses, indications for MV, MV modes and settings, and prognoses on the 60th day were collected. Multivariable logistic analysis was used to assess factors that might affect the use of LPV. Results： A total of 104 patients were enrolled in the present study, 87 （83.7%） of whom were identified with severe brain injury based on a Glasgow Coma Scale 〈8 points. Synchronized intermittent mandatory ventilation （SIMV） was the most frequent ventilator mode, accounting for 46.2% of the entire cohort. The median tidal volume was set to 8.0 ml/kg （interquartile range [IQR], 7.0-8.9 ml/kg） of the predicted body weight; 50 （48.1%） patients received LPV. The median positive end-expiratory pressure （PEEP） was set to 5 cmH20 （IQR, 5-5 cmH20）. No PEEP values were higher than 10 cmH20. Compared with partially mandatory ventilation, supportive and spontaneous ventilation practices were associated with LPV. There were no significant differences in mortality and MV duration between patients subjected to LPV and those were not. Conclusions： Among brain-injured patients in China, SIMV was the most frequent ventilation mode. Nearly one-half of the brain-injured patients received LPV. Patients under supportive and spontaneous ventilation were more likely to receive LPV.

关键词： Brain Injury Epidemiology Lung-protective Ventilation Mechanical Ventilation

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： Hai-dong Zhu Hai-Liang Li ming-Sheng huang Wei-Zhu yang Guo-Wen Yin bin-yan zhong Jun-hui Sun Zhi-cheng Jin Jian-Jian chen Nai-Jian Ge Wen-bin Ding Wen-hui Li Jin-hua huang Wei Mu Shan-Zhi Gu Jia-ping Li hui Zhao Shu-Wei Wen yan-ming Lei Yu-Sheng Song Chun-Wang yuan Wei-dong Wang ming huang Wei Zhao Jian-bing Wu Song Wang Xu Zhu Jian-Jun Han Wei-Xin Ren Zai-ming Lu Wen-Ge Xing Yong Fan Hai-Lan Lin Zi-Shu Zhang Guo-hui Xu Wen-Hao hu Qiang Tu hong-Ying Su Chuan-Sheng Zheng Yong chen Xu-Ya Zhao Zhu-Ting Fang Qi Wang Jin-Wei Zhao Ai-bing Xu Jian Xu Qing-hua Wu huan-Zhang Niu Jian Wang feng Dai Dui-ping feng Qing-dong Li Rong-Shu Shi Jia-Rui Li Guang yang Hai-bin Shi Jian-Song Ji Yu-E Liu Zheng Cai Po yang yang Zhao Xiao-Li Zhu Li-Gong Lu Gao-Jun Teng Center of Interventional Radiology&Vascular Surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China Department of Minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China Department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China Department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China Department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China Department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China Hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China Department of Interventional Radiology Nantong First People’s HospitalNantong 226001China Department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China Department of Minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China Department of Vascular Surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. Department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China Department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China Department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China Department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China Department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;Pbination and monotherapy groups,*** results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

The first data release(DR1) of the LAMOST regular survey

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-Li Luo Yong-Heng Zhao Gang Zhao Li-Cai Deng Xiao-Wei Liu Yi-Peng Jing Gang Wang Hao-Tong Zhang Jian-Rong Shi Xiang-Qun Cui Yao-Quan Chu Guo-ping Li zhong-Rui Bai Yue Wu yan Cai Shu-Yun Cao Zi-huang Cao Jeffrey L.Carlin Hai-yuan chen Jian-Jun chen Kun-Xin chen Li chen Xue-Lei chen Xiao-yan chen Ying chen Norbert Christlieb Jia-Ru Chu chen-Zhou Cui Yi-Qiao dong bing Du dong-Wei Fan Lei feng Jian-Ning Fu Peng Gao Xue-Fei Gong Bo-zhong Gu yan-Xin Guo Zhan-Wen Han Bo-Liang He Jin-Liang Hou Yong-hui Hou Wen Hou hong-Zhuan hu Ning-Sheng hu zhong-Wen hu Zhi-Ying huo Lei Jia Fang-hua Jiang Xiang Jiang Zhi-Bo Jiang Ge Jin Xiao Kong Xu Kong Ya-Juan Lei Ai-hua Li Chang-hua Li Guang-Wei Li Hai-Ning Li Jian Li Qi Li Shuang Li Sha-Sha Li Xin-Nan Li yan Li Yin-Bi Li Ye-ping Li yuan Liang Chien-cheng Lin Chao Liu Gen-Rong Liu Guan-Qun Liu Zhi-Gang Liu Wen-Zhi Lu Yu Luo Yin-Dun Mao Heidi Newberg Ji-Jun Ni Zhao-Xiang Qi Yong-Jun Qi Shi-Yin Shen huo-ming Shi Jing Song Yi-Han Song Ding-Qiang Su hong-Jun Su Zheng-hong Tang Qing-Sheng Tao yuan Tian Dan Wang Da-Qi Wang feng-Fei Wang Guo-Min Wang Hai Wang hong-Chi Wang Jian Wang Jia-Ning Wang Jian-Ling Wang Jian-ping Wang Jun-Xian Wang Lei Wang Meng-Xin Wang shou-Guan Wang Shu-Qing Wang Xia Wang Ya-Nan Wang You Wang Yue-Fei Wang You-Fen Wang Peng Wei ming-Zhi Wei hong Wu Ke-Fei Wu Xue-bing Wu Yu-zhong Wu Xiao-Zheng Xing Ling-Zhe Xu Xin-Qi Xu yan Xu Tai-Sheng yan De-hua yang Hai-feng yang hui-Qin yang ming yang Zheng-Qiu Yao Yong Yu hui yuan Hai-Bo yuan Hai-Long yuan Wei-Min yuan Chao Zhai En-Peng Zhang hua-Wei Zhang Jian-Nan Zhang Li-Pin Zhang Wei Zhang Yong Zhang yan-Xia Zhang Zheng-Chao Zhang ming Zhao Fang Zhou Xu Zhou Jie Zhu Yong-Tian Zhu Si-cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University Yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in June 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in June 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

Data release of the LAMOST pilot survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2012年第9期12卷 1243-1246页

作者： A-Li Luo Hao-Tong Zhang Yong-Heng Zhao Gang Zhao Xiang-Qun Cui Guo-ping Li Yao-Quan Chu Jian-Rong Shi Gang Wang Jian-Nan Zhang zhong-Rui Bai Xiao-yan chen feng-Fei Wang yan-Xin Guo Jian-Jun chen bing Du Xiao Kong Ya-Juan Lei Yin-Bi Li Yi-Han Song Yue Wu yan-Xia Zhang Xin-Lin Zhou Fang Zuo Peng Du Lin He Wen Hou Yi-Qiao dong Jian Li Guang-Wei Li Shuang Li Jing Song yuan Tian Meng-Xin Wang Yong-hui Hou Zhi-Ying huo hong-Zhuan hu Ning-Sheng hu zhong-Wen hu Lei Jia Fang-hua Jiang Xiang Jiang Zi-Bo Jiang Ge Jin Ai-hua Li Qi Li Yin-Dun Mao Zheng-hong Tang Qing-Sheng Tao Liang-ping Tu Da-Qing Wang Dan Wang Jian-ping Wang Lei Wang shou-Guan Wang Shu-Qing Wang Ya-Nan Wang You Wang Yue-Fei Wang ming-Zhi Wei Xiang-Xiang Xue Xiao-Zheng Xing Ling-Zhe Xu Xin-Qi Xu yan Xu De-hua yang Shi-Hai yang Zheng-Qiu Yao Yong Yu hui yuan Chao Zhai En-Peng Zhang Jing Zhang Li-ping Zhang WeiZhang Yong Zhang Zhen-Chao Zhang ming Zhao Fang Zhou Yong-Tian Zhu Jie Zhu Si-cheng Zou National Astronomical Observatories Chinese Academy of Sciences Beijing 100012 China lal @ lamost o rg Nanjing Institute of Astronomical Optics and Technology National Astronomical ObservatoriesChinese Academy of Sciences Nanjing 210042 China University of Science and Technologyof China Hefei 230026 China Shanghai Astronomical Observatory Chinese Academy of Sciences Shanghai 200030 China Institute of Architecture Design and Research Chinese Academy of Sciences Beijing 100190China

This paper describes the data release of the LAMOST pilot survey, which includes data reduction, calibration, spectral analysis, data products and data access. The accuracy of the released data and the information about the FITS headers of spectra are also introduced. The released data set includes 319 000 spectra and a catalog of these objects.

关键词： techniques: spectroscopic survey — data reduction — data release

2018 Chinese Pediatric Cardiology Society(CPCS) guideline for diagnosis and treatment of syncope in children and adolescents

在线全文

学校读者我要写书评

暂无评论

Science Bulletin 2018年第23期63卷 1558-1564页

作者： cheng Wang Yaqi Li Ying Liao hong Tian Min huang Xiangyu dong Lin Shi Jinghui Sun hongfang Jin Junbao Du Jindou An Jie chen mingwu chen Qi chen Sun chen Yonghong chen Zhi chen Adolphus Kai-tung Chau Junbao Du zhongdong Du Junkai Duan hongyu Duan Xiangyu dong Lin feng Lijun Fu Fangqi Gong Yonghao Gui Ling Han Zhenhui Han bing He Zhixu He Xiufen hu Yimin hua Guoying huang Min huang ping huang Yujuan huang hongfang Jin Mei Jin Bo Li Fen Li Tao Li Xiaohui Li Xiaoyan Liu yan Li Haitao Lv Tiewei Lv Zipu Li Luyi Ma Silin Pan Yusheng Pang hua Peng Yuming Qin Jie Shen Lin Shi Kun Sun Jinghui Sun hong Tian Jie Tian cheng Wang hong Wang Lei Wang Jinju Wang Wendi Wang Yuli Wang Rongzhou Wu Tianhe Xia yanyan Xiao Chunhong Xie yanlin Xing Zhenyu Xiong Baoyuan Xu Yi Xu hui yan Shiwei yang Qijian Yi Xia Yu Xianyi Yu Yue yuan hongyan Zhang huili Zhang Li Zhang Qingyou Zhang Xi Zhang yanmin Zhang Zhiwei Zhang Cuifen Zhao bin Zhou hua Zhu Department of Pediatric Cardiovasoloy Children's Medical CenterThe Second Xiangya HospitalCentral South UniversityChangsha 410071China Department of Pediatrics Peking University First HospitalBeijing 100034China Department of Pediatric Cardiology Children's Hospital of Fudan UniversityShanghai 201102China Department of Pediatric Cardiology Shanghai Children's HospitalShanghai 207102China of Pediatrics the 2nd Hospital of Lanzhou UniversityLanzhou 730020China Department of Pediatric Cardiology Capital Institute of PediatricsBezjing 100020China Department of Pediatrics Jilin University First HospitalChangchun 130021China Chinese Pediatric Cardiology Society Chinese Pediatric Society(CPCS)Chinese Medical Association(CMA)China Committee on Pediatric Syncope Pediatricians BranchChinese Medical Doctor Association(CMDA)China Pediatric Cardiology Society Beijing Pediatric SocietyBeijing Medical Association(BMA)China Committee on Pediatric Cardiology Chinese College of Cardiovascular PhysiciansChinese Medical Doctor Association(CMDA)China

Syncope belongs to the transient loss of consciousness(TLOC), characterized by a rapid onset, short duration, and spontaneous complete recovery. It is common in children and adolescents, accounting for 1% to 2% of emergency department *** syncope can seriously affect children's physical and mental health, learning ability and quality of life and sometimes cardiac syncope even poses a risk of sudden death. The present guideline for the diagnosis and treatment of syncope in children and adolescents was developed for guiding a better clinical management of pediatric syncope. Based on the globally recent development and the evidence-based data in China, 2018 Chinese Pediatric Cardiology Society(CPCS) guideline for diagnosis and treatment of syncope in children and adolescents was jointly prepared by the Pediatric Cardiology Society, Chinese Pediatric Society, Chinese Medical Association(CMA)/Committee on Pediatric Syncope, Pediatricians Branch, Chinese Medical Doctor Association(CMDA)/Committee on Pediatric Cardiology, Chinese College of Cardiovascular Physicians, Chinese Medical Doctor Association(CMDA)/Pediatric Cardiology Society, Beijing Pediatric Society, Beijing Medical Association(BMA). The present guideline includes the underlying diseases of syncope in children and adolescents, the diagnostic procedures, methodology and clinical significance of standing test and headup tilt test, the clinical diagnosis vasovagal syncope, postural orthostatic tachycardia syndrome, orthostatic hypotension and orthostatic hypertension, and the treatment of syncope as well as follow-up.

关键词： CPCS Children Adolescent syncope

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1:interim analysis of the randomized,controlled,phase 3,non-inferiority TALENT study

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2020年第24期133卷 2919-2927页

作者： bin Su cheng Yao Qing-Xia Zhao Wei-ping Cai Min Wang hong-Zhou Lu yuan-yuan chen Li Liu hui Wang Yun He Yu-huang Zheng Ling-hua Li Jin-feng chen Jian-hua Yu Biao Zhu Min Zhao Yong-Tao Sun Wen-hui Lun Wei Xia Li-Jun Sun Li-Li Dai Tai-Yi Jiang Mei-Xia Wang Qing-Shan Zheng Hai-yan Peng Yao Wang Rong-Jian Lu Jian-hua hu hui Xing Yi-ming Shao dong Xie Tong Zhang Fu-Jie Zhang Hao Wu TALENT Study Team Center for Infectious Diseases Beijing Youan HospitalCapital Medical UniversityBeijing 100069China Frontier Biotechnologies Inc. NanjingJiangsu 211122China Department of Infectious Diseases Infectious Disease Hospital of Henan ProvinceZhengzhouHenan 450061China Infectious Disease Center Guangzhou Eighth People’s HospitalGuangzhou Medical UniversityGuangzhouGuangdong 510060China Institute of HIV/AIDS The First Hospital of ChangshaChangshaHunan 410005China Department of Infectious Diseases Shanghai Public Health Clinical CenterFudan UniversityShanghai 201508China Department of Infectious Diseases National Clinical Center for Infectious DiseasesShenzhen Third People’s HospitalShenzhenGuangdong 518112China Department of Infectious Diseases The Second Xiangya HospitalCentral South UniversityChangshaHunan 410011China Department of Infectious Diseases Xixi Hospital of HangzhouHangzhouZhejiang 310023China State Key Laboratory for Diagnosis and Treatment of Infectious Diseases National Clinical Research Center for Infectious DiseasesThe First Affiliated HospitalZhejiang UniversityHangzhouZhejiang 310003China National Clinical Research Center for Infectious Diseases the Fifth Medical Center of PLA General HospitalBeijing 100039China Department of Infectious Diseases Tangdu HospitalThe Fourth Military Medical UniversityXi’anShaanxi 710038China Clinical and Research Center of Infectious Diseases Beijing Ditan HospitalCapital Medical UniversityBeijing 100015China Center for Drug Clinical Research Shanghai University of Traditional Chinese MedicineShanghai 201203China Beijing Co-CRO Medical Development Co. Ltd.Beijing 100711China State Key Laboratory for Infectious Disease Prevention and Control National Center for AIDS/STD Control and PreventionChinese Center for Disease Control and PreventionBeijing 102206China 不详

Background:Albuvirtide is a once-weekly injectable human immunodeficiency virus(HIV)-1 fusion *** present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral ***:We carried out a 48-week,randomized,controlled,open-label non-inferiority trial at 12 sites in *** on the World Health Organization(WHO)-recommended first-line treatment for>6 months with a plasma viral load>1000 copies/mL were enrolled and randomly assigned(1:1)to receive albuvirtide(once weekly)plus ritonavir-boosted lopinavir(ABT group)or the WHO-recommended second-line treatment(NRTI group).The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 ***-inferiority was prespecified with a margin of 12%.Results:At the time of analysis,week 24 data were available for 83 and 92 patients,and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups,*** 48 weeks,80.4%of patients in the ABT group and 66.0%of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL,meeting the criteria for *** the per-protocol population,the superiority of albuvirtide over NRTI was *** frequency of grade 3 to 4 adverse events was similar in the two groups;the most common adverse events were diarrhea,upper respiratory tract infections,and grade 3 to 4 increases in triglyceride *** function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT ***:The TALENT study is the first phase 3 trial of an injectable long-acting HIV *** interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatme

关键词： HIV Fusion inhibitor Albuvirtide LPV/r Phase 3 clinical trial

Searching for ^(76)Ge neutrinoless double beta decay with the CDEX-1B experiment

在线全文

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第10期48卷 11-22页

作者： bing-Tao Zhang Jun-Zheng Wang Li-Tao yang Qian Yue Ke-Jun Kang yuan-Jing Li Hai-Peng An C.Greeshma Jian-ping Chang Yun-huan chen Jian-ping cheng Wen-Han Dai Zhi Deng Chang-Hao Fang Xin-ping Geng hui Gong Qiu-Ju Guo Xu-yuan Guo Li He Sheng-ming He Jin-Wei hu Han-Xiong huang Tu-chen huang Hai-Tao Jia Xi Jiang S.Karmakar Hao-bin Li Jian-Min Li Jin Li Qian-Yun Li Ren-ming-Jie Li Xue-Qian Li Yu-Lan Li Yi-Fan Liang bin Liao Fong-Kay Lin Shin-Ted Lin Jia-Xuan Liu Shu-Kui Liu yan-dong Liu Yu Liu yuan-yuan Liu zhong-Zhi Liu Hao Ma Yu-Cai Mao Qi-yuan Nie Jin-hua Ning hui Pan Ning-Chun Qi Jie Ren Xi-Chao Ruan Ze She Manoj Kumar Singh Tian-Xi Sun Chang-Jian Tang Wei-You Tang yang Tian Guang-Fu Wang Li Wang Qing Wang Yu-feng Wang Yun-Xiang Wang Henry-Tsz-King Wong Shi-Yong Wu Yu-cheng Wu Hao-yang Xing Rui Xu Yin Xu Tao Xue Yu-Lu yan Nan Yi Chun-Xu Yu Hai-Jun Yu Jian-feng Yue ming Zeng Zhi Zeng feng-shou Zhang Lei Zhang Zhen-hua Zhang Zhen-Yu Zhang Kang-Kang Zhao ming-Gang Zhao Ji-Fang Zhou Zu-Ying Zhou Jing-Jun Zhou Key Laboratory of Particle and Radiation Imaging(Ministry of Education)and Department of Engineering Physics Tsinghua UniversityBeijing 100084 Department of Physics Tsinghua UniversityBeijing 100084 Institute of Physics Academia SinicaTaipei 11529 NUCTECH Company Beijing 100084 YaLong River Hydropower Development Company Chengdu 610051 College of Nuclear Science and Technology Beijing Normal UniversityBeijing 100875 College of Physics Sichuan UniversityChengdu 610065 School of Physics Peking UniversityBeijing 100871 Department of Nuclear Physics China Institute of Atomic EnergyBeijing 102413 Sino-French Institute of Nuclear and Technology Sun Yat-sen UniversityZhuhai 519082 School of Physics Nankai UniversityTianjin 300071 Department of Physics Banaras Hindu UniversityVaranasi 221005 Department of Physics Beijing Normal UniversityBeijing 100875

We operated a p-type point contact high purity germanium(PPCGe)detector(CDEX-1B,1.008 kg)in the China Jinping Underground Laboratory(CJPL)for 500.3 days to search for neutrinoless double beta(0νββ)decay of ^(76)Ge.A total of 504.3 kg⋅day effective exposure data was *** anti-coincidence and the multi/single-site event(MSE/SSE)discrimination methods were used to suppress the background in the energy region of interest(ROI,1989–2089 keV for this work)with a factor of 23.A background level of 0.33 counts/(keV⋅kg⋅yr)was *** lower limit on the half life of^(76)Ge 0νββdecay was constrained as T_(1/2)^(0ν)>1.0×10^(23)yr(90%C.L.),corresponding to the upper limits on the effective Majorana neutrino mass:<3.2–7.5 eV.

关键词： neutrinoless double beta decay CDEX point-contact germanium detector ^(76)Ge